A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda), tested in patients with metastatic melanoma
Continue reading »![](https://mypharmacynews.com/wp-content/uploads/sites/11/2018/04/YdkSJrojcEbwGtGIlNoj.jpg)
mypharmacynews.com
Home ยป
A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda), tested in patients with metastatic melanoma
Continue reading »